Has David Allen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $418 in general payments to David Allen, MD across 13 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Allen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Allen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Allen, MD

Neurological Surgery · Reading, PANPI 1881652733

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by United Therapeutics Corporation at 33.3% of the total. Reporting peaked in 2020 at $155 and has fallen 70.3% since, to $46 in 2025. That places this record below the midpoint for neurological surgery clinicians in PA, where the typical reported total is $3,234.

$418in general payments, 2019–2025

Across 13 payments — averaging $32.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

United Therapeutics Corporation$139
Pfizer$73
Abbott$61
Bridgebio Pharma, Inc.$46
Boston Scientific$40
AbbVie$27
plus $32 from 2 others

What the payments were for

Food & beverage$418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
United Therapeutics Corporation	2	$139
Pfizer	4	$73
Abbott	1	$61
Bridgebio Pharma, Inc.	1	$46
Boston Scientific	2	$40
AbbVie	1	$27
Medtronic	1	$18
Nevro Corp.	1	$15

How this compares

$418 in reported general payments places this provider in the 20th percentile of 390 neurological surgery providers in Pennsylvania.

See all neurological surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$25,618

Medicare patients

102

Services billed

224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tizanidine Hcl	197	$3,797
Celecoxib	57	$1,979
Diclofenac Sodium	131	$1,910
Gabapentin	73	$1,334
Ibuprofen	45	$661
Methocarbamol	47	$402
Oxycodone Hcl	14	$251
Tramadol Hcl	43	$241
Acetaminophen-CodeineAcetaminophen With Codeine	16	$219
Methylprednisolone	21	$204
Naproxen	20	$178
Oxybutynin Chloride	18	$132
Diazepam	12	$106
Prednisone	14	$102
Cyclobenzaprine Hcl	13	$81

Paid to pharmacies, not to this prescriber.